Ntrk Gene Fusion Positive Tumors Therapeutics
1. Rozlytrek patent expiration
Treatment: Treatment of ros1-positive non-small cell lung cancer; Treatment of solid tumors that have a neurotrophic tyrosine receptor kinase (ntrk) gene fusion; Treatment of neuroblastomas that have a neurotrop...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10738037 | GENENTECH | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(11 years from now) | |
| US8299057 | GENENTECH | Substituted indazole derivatives active as kinase inhibitors |
Mar, 2032
(6 years from now) | |
| US9085565 | GENENTECH | Process for the preparation of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(7 years from now) | |
| US9029356 | GENENTECH | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9649306 | GENENTECH | Treatment of diseases through administration of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2033
(7 years from now) | |
| US9255087 | GENENTECH | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(2 years from now) | |
| US10231965 | GENENTECH | Molecules for administration to ROS1 mutant cancer cells |
Feb, 2035
(8 years from now) | |
| US9616059 | GENENTECH | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(2 years from now) | |
| US8673893 | GENENTECH | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(2 years from now) | |
| US10561651 | GENENTECH | Methods for treating neuroblastoma |
Feb, 2035
(8 years from now) | |
| US9085558 | GENENTECH | Substituted indazole derivatives active as kinase inhibitors |
Jul, 2028
(2 years from now) | |
| US11091469 | GENENTECH | Crystalline form of N-[5-(3,5-difluoro-benzyl)-1H-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4-ylamino)-benzamide |
May, 2037
(11 years from now) | |
| US11253515 | GENENTECH | Pharmaceutical compositions and dosage forms |
Jul, 2038
(12 years from now) | |
| US10398693 | GENENTECH | Pharmaceutical compositions and dosage forms |
Jul, 2038
(12 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Aug 15, 2024 |
| ODE*(ODE*) | Aug 15, 2026 |
| Orphan Drug Exclusivity(ODE-265) | Aug 15, 2026 |
| Orphan Drug Exclusivity(ODE-313) | Aug 15, 2026 |
| New Product(NP) | Oct 20, 2026 |
| New Patient Population(NPP) | Oct 20, 2026 |
| Orphan Drug Exclusivity(ODE-448) | Oct 20, 2030 |
Drugs and Companies using ENTRECTINIB ingredient
NCE-1 date: 16 August, 2023
Market Authorisation Date: 15 August, 2019
Dosage: CAPSULE
More Information on Dosage
ROZLYTREK family patents
2. Vitrakvi patent expiration
Treatment: Method of treating cmn, ifs, hgg, dipgs, ptc, soft tissue sarcoma, and spindle cell sarcoma solid tumors exhibiting an ntrk gene fusion in a pediatric patient with an oral solution; Method of treating...
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US10799505 | BAYER | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Aug, 2036
(10 years from now) | |
| US8513263 | BAYER | Substituted pyrazolo[1,5-a]pyrimidine compounds as Trk kinase inhibitors |
Dec, 2029
(3 years from now) | |
| US10172861 | BAYER | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(9 years from now) | |
| US9127013 | BAYER | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10045991 | BAYER | Methods of treating pediatric cancers |
Apr, 2037
(11 years from now) | |
| US11191766 | BAYER | Methods of treating pediatric cancers |
Apr, 2037
(11 years from now) | |
| US11484535 | BAYER | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a] pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(11 years from now) | |
| US9782414 | BAYER | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(9 years from now) | |
| US10005783 | BAYER | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(3 years from now) | |
| US10047097 | BAYER | Method of treatment using substituted pyrazolo[1,5-a] pyrimidine compounds |
Oct, 2029
(3 years from now) | |
| US10813936 | BAYER | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-YL)-pyrazolo[1,5-A]pyrimidin-3-YL)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(9 years from now) | |
| US9676783 | BAYER | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(3 years from now) | |
| US8865698 | BAYER | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(3 years from now) | |
| US9447104 | BAYER | Method of treatment using substituted pyrazolo[1,5-a]pyrimidine compounds |
Oct, 2029
(3 years from now) | |
| US10285993 | BAYER | Crystalline form of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide hydrogen sulfate |
Nov, 2035
(9 years from now) | |
| US10774085 | BAYER | Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds |
Oct, 2029
(3 years from now) | |
| US11974998 | BAYER | Methods of treatment |
May, 2037
(11 years from now) | |
| US11337967 | BAYER | Methods of treatment |
May, 2037
(11 years from now) | |
| US10668072 | BAYER | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-a]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(11 years from now) | |
| US10137127 | BAYER | Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo[1,5-A]pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide |
Apr, 2037
(11 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Nov 26, 2023 |
| Orphan Drug Exclusivity(ODE-215) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-220) | Nov 26, 2025 |
| Orphan Drug Exclusivity(ODE-221) | Nov 26, 2025 |
Drugs and Companies using LAROTRECTINIB SULFATE ingredient
NCE-1 date: 26 November, 2022
Market Authorisation Date: 26 November, 2018
Dosage: SOLUTION; CAPSULE
How can I launch a generic of VITRAKVI before it's drug patent expiration?
More Information on Dosage
VITRAKVI family patents